Telehealth is fastest growing segment fueling the growth of the Global Abortion Drugs Market
Abortion Drugs Market |
Market Overview:
The global Abortion Drugs Market
is estimated to be valued at US$ 3.53 Bn in 2023 and is expected to exhibit a
CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new
report published by Coherent Market Insights.
Abortion drugs terminate early
pregnancy (up to 10 weeks of gestation) via two major mechanisms- interfering
with hormonal functions required for maintaining pregnancy or interfering with
implantation process. These drugs help women avoid risks, costs, and stigma
associated with surgical abortions.
Market key trends:
One of the major trends in the
abortion drugs market is increasing preference for medical abortions over
surgical abortions. This is due to advantages associated with medical abortions
such as privacy, convenience, and being less invasive than surgical methods.
According to Guttmacher Institute, medical abortions now account for over half
of all abortions in the U.S. and the proportion is growing by 10% each year.
Countries across the world are also liberalizing laws allowing easier access to
medical abortion drugs, contributing to the growing adoption of these drugs.
Segment Analysis
The abortion drugs market is
segmented into Mifepristone and Misoprostol. The Mifepristone segment currently
dominates the market with over 65% share due to its use as the key ingredient
in medical abortion. Mifepristone helps in terminating pregnancy by blocking
the action of the hormone progesterone, which is essential to sustain
pregnancy.
Key Takeaways
The Global
Abortion Drugs Market Share is expected to witness high growth,
exhibiting CAGR of 7.4% over the
forecast period, due to increasing legalization of abortion drugs for
overcoming restrictions on surgical abortions.
Regional analysis
North America currently dominates
the abortion drugs market with over 35% share owing to easy accessibility of
abortion pills. However, Asia Pacific is expected to grow at the fastest pace
during the forecast period due to continually improving healthcare
infrastructure and growing awareness about women's health and rights.
Key players
Key players operating in the
abortion drugs market are AbbVie, Mylan Pharmaceuticals, Gedeon Richter, HRA
Pharma, Cipla Ltd, Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd, Sun
Pharmaceutical Industries Ltd, Torrent Pharmaceuticals Ltd, Mankind Pharma Ltd.
AbbVie leads the market with its blockbuster drug Mifegyne for medical
abortion.
Get More Insights Here
https://www.newsstatix.com/abortion-drugs-market-share-size-forecast-outlook-2023-2030/
Comments
Post a Comment